Skip Ribbon Commands
Skip to main content

Mrs Kylie Sproston

Chief Executive Officer
Bellberry Limited

Kylie Sproston is CEO of Bellberry, a not-for-profit organisation providing streamlined scientific and ethical review of Human Research projects across Australia.  As a not-for-profit organisation, Bellberry invests all proceeds back into the research community through fellowships, Research Infrastructure and Project Grant funding. 

A Chartered Engineer, Kylie has expertise across the full pharmaceutical product lifecycle, and has held key positions in both technical and management disciplines in the global Pharmaceutical and Biotech industries. Kylie previously led and managed the Australasian operations of the global group BTG PLC (a specialist healthcare company based in London, UK), as General Manager and Company Director.  Prior to that, Kylie undertook a number of roles within various functions in the Global company AstraZeneca.

Kylie received an MEng (Hons) in Mechanical Engineering from Loughborough University (UK) and an MSc in Pharmaceutical Engineering Advanced Training from University of Manchester (UK). She is a Graduate of the AICD Company Directors Course.

Presentation Title

Patient Centric Approach to Enhance Conduct of Research – Ethical Considerations

More than 50% of trials in global databases are terminated due to a failure to complete recruitment targets, yet the vast majority of the community are supportive of the concept of clinical trials and research.  In an effort to address this discrepancy, jurisdictions and funding agencies around the world are placing greater emphasis on the voice of the community in research.

In this session we will explore a range of participant- and patient-focussed policies aimed at improving the community voice in the design, assessment and implementation of research.  We will look at participant-oriented trial innovations such as remote screening, econsent, drug distribution practices and decentralization of trials.  In looking at such practices we will discuss the implications for both sites and IRBs.  Finally, we will consider policies and practices to support the participant when research results in unexpected outcomes such as research integrity issues, participant complaint matters, and incidental findings.

Our aim will be to improve the awareness and implementation of participant-centred practices within IRBs and institutions.

< Back to Speakers' Information